Narlaprevir
- Generic Name
- Narlaprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C36H61N5O7S
- CAS Number
- 865466-24-6
- Unique Ingredient Identifier
- 2857LA2O07
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 85
- Registration Number
- NCT04246723
- Locations
- 🇷🇺
FBIS CSRI of Epidemiology of Federal Service on Customers, Moscow, Russian Federation
🇷🇺FSIS FRC of food and biotechnology, Moscow, Russian Federation
🇷🇺SBEI HPE MSMDU n.a. A.I. Evdokimov of Ministry of Health of Russia, Moscow, Russian Federation
Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2019-02-07
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 420
- Registration Number
- NCT03833362
- Locations
- 🇷🇺
South-Ural State Medical University, Clinic of Medical Academy, Infectious Diseases Department, Chelyabinsk, Russian Federation
🇷🇺First Moscow State Medical University n.a. I.M. Sechenov, Clinic of Nephrology, Internal and Professional Diseases n.a. E.M. Tarleev, Moscow, Russian Federation
🇷🇺Moscow State Medical Stomatological University n.a. A. I. Evdokimov, Clinical Infectious Hospital #1, Clinical Infections Department, Moscow, Russian Federation
A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 32
- Registration Number
- NCT03832426
- Locations
- 🇬🇪
LLC Chapidze Emergency Cardiology Center, Tbilisi, Georgia
🇬🇪LLC Guli (Heart) - Cardiology clinic, Tbilisi, Georgia
🇷🇺- Institution of the Russian Academy of Sciences "RAS Hospital", Troitsk, Russian Federation
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
- Conditions
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 36
- Registration Number
- NCT03537404
- Locations
- 🇷🇺
Clinic "Bessalar" JSC, Moscow, Russian Federation
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b
- Conditions
- Interventions
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 105
- Registration Number
- NCT03485846
- Locations
- 🇷🇺
FBIS CSRI of Epidemiology of Federal Service on Customers, Moscow, Russian Federation
🇷🇺St. Petersburg SBHI Center of Prevention and Fight against AIDS and Infection Diseases, Saint Petersburg, Russian Federation
🇷🇺SBEI HPE Moscow State Medical and Dental University n.a. A.I. Evdokimov of Ministry of Health of Russia, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.